plasma-p-tau181

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

1. 72/100

   Plasma p-tau181 and GFAP reflect 7T MR-derived changes in Alzheimer's disease: A longitudinal study of structural and functional MRI and MRS

   ✓ Peer-reviewed alzhub usefulness score 72 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024-11-19 · Biomarkers

   Both plasma p-tau181 and GFAP appear to reflect disease progression, as indicated by 7T MR-derived brain changes which are not limited to areas known to be affected by tau pathology and neuroinflammation measured by MRS myo-inositol, respectively.

   • Biomarkers
   • Brain Scans
   • Brain Biology
2. 47/100

   Plasma p-tau181 and amyloid markers in Alzheimer's disease: A comparison between Lumipulse and SIMOA

   ✓ Peer-reviewed alzhub usefulness score 47 out of 100. Neurobiology of aging · 2024-08-22 · Biomarkers

   One-hundred-thirthy-three participants, namely 55 A+T+N+ AD, 28 Neurodegenerative disorders (NDD) and 50 controls were enrolled for the study.

   • Biomarkers
3. 45/100

   Plasma p-tau181 as a promising non-invasive biomarker of Alzheimer's Disease pathology in Subjective Cognitive Decline and Mild Cognitive Impairment

   ✓ Peer-reviewed alzhub usefulness score 45 out of 100. Journal of the neurological sciences · 2023-09-12 · Biomarkers

   Plasma p-tau181 levels were influenced by the presence of underlying AD pathology, independently from the cognitive status and were highly accurate in differentiating SCD-MCI patients who were carriers of AD pathology from non-carriers.

   • Biomarkers
   • Early Stage
4. 67/100

   Elevated plasma p-tau181 levels unrelated to Alzheimer's disease pathology in amyotrophic lateral sclerosis

   ✓ Peer-reviewed alzhub usefulness score 67 out of 100. Journal of neurology, neurosurgery, and psychiatry · 2023-04-03 · Biomarkers

   Plasma p-tau181 is elevated in patients with ALS, independently from CSF levels, and is firmly associated with LMN dysfunction.

   • Biomarkers
   • Other Dementias
5. 52/100

   CSF biomarkers and plasma p-tau181 as predictors of longitudinal tau accumulation: Implications for clinical trial design

   ✓ Peer-reviewed alzhub usefulness score 52 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association · 2022-02-28 · Biomarkers

   Clinical trials testing tau-targeting therapies may benefit from using fluid biomarkers to recruit individuals at risk of tau aggregation.

   • Biomarkers
   • Clinical Trials
   • Brain Biology
6. 59/100

   Association of APOE ɛ4 and Plasma p-tau181 with Preclinical Alzheimer's Disease and Longitudinal Change in Hippocampus Function

   ✓ Peer-reviewed alzhub usefulness score 59 out of 100. Journal of Alzheimer's disease : JAD · 2022-01-01 · Biomarkers

   Our findings support an association of APOE ɛ4 and p-tau181 with preclinical AD and hippocampus functioning.

   • Biomarkers
   • Genetics
   • Early Stage
7. 74/100

   Association of plasma P-tau181 with memory decline in non-demented adults

   ✓ Peer-reviewed alzhub usefulness score 74 out of 100. Brain communications · 2021-06-14 · Biomarkers

   Mixed-effect models assessed rates of memory decline in relation to baseline plasma p-tau181, and whether plasma p-tau181 significantly predicted memory decline beyond widely available clinical and genetic data (age, sex, years of education, cardiovascular and metabolic conditions, and APOE ε 4 status).

   • Biomarkers

All topic tags with their study counts